Bolette Hartmann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1681393/publications.pdf

Version: 2024-02-01

219	8,531	41323	60583
papers	citations	49 h-index	81 g-index

220	220	220	6226
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology, 2001, 120, 806-815.	0.6	490
2	Role of Gastrointestinal Hormones in Postprandial Reduction of Bone Resorption. Journal of Bone and Mineral Research, 2003, 18, 2180-2189.	3.1	272
3	Minimal enteral nutrient requirements for intestinal growth in neonatal piglets: how much is enough?. American Journal of Clinical Nutrition, 2000, 71, 1603-1610.	2.2	210
4	Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides, 2000, 21, 73-80.	1.2	196
5	Intake of Lactobacillus reuteri Improves Incretin and Insulin Secretion in Glucose-Tolerant Humans: A Proof of Concept. Diabetes Care, 2015, 38, 1827-1834.	4.3	194
6	GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regulatory Peptides, 2005, 124, 105-112.	1.9	179
7	GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1 1This work is a publication of the USDA/ARS Childrenâ€™s Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine and Texas Childrenâ€™s Hospital, Houston, Texas.. Gastroenterology, 2003, 125, 136-147.	0.6	165
8	Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?. Diabetologia, 2014, 57, 1919-1926.	2.9	156
9	Inhibition of Sham Feeding-Stimulated Human Gastric Acid Secretion by Glucagon-Like Peptide-2. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2513-2517.	1.8	146
10	Four-month treatment with GLP-2 significantly increases hip BMD. Bone, 2009, 45, 833-842.	1.4	144
11	The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. American Journal of Physiology - Renal Physiology, 2013, 304, G1117-G1127.	1.6	138
12	Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes, 2016, 65, 585-597.	0.3	136
13	Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas. Molecular Metabolism, 2018, 11, 84-95.	3.0	135
14	An Analysis of Cosecretion and Coexpression of Gut Hormones From Male Rat Proximal and Distal Small Intestine. Endocrinology, 2015, 156, 847-857.	1.4	128
15	In Vivo and in Vitro Degradation of Glucagon-Like Peptide-2 in Humans1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2884-2888.	1.8	126
16	Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. American Journal of Physiology - Endocrinology and Metabolism, 2000, 278, E1010-E1018.	1.8	119
17	Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. Diabetes, 2019, 68, 906-917.	0.3	118
18	Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. European Journal of Endocrinology, 2014, 170, 529-538.	1.9	116

#	Article	IF	Citations
19	GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2909-2917.	1.8	116
20	Disassociation of bone resorption and formation by GLP-2. Bone, 2007, 40, 723-729.	1.4	106
21	Onset of Small Intestinal Atrophy Is Associated with Reduced Intestinal Blood Flow in TPN-Fed Neonatal Piglets. Journal of Nutrition, 2004, 134, 1467-1474.	1.3	105
22	Glucose-Dependent Insulinotropic Polypeptide Inhibits Bone Resorption in Humans. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2325-E2329.	1.8	104
23	Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone, 2004, 34, 140-147.	1.4	103
24	Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans. American Journal of Physiology - Renal Physiology, 2014, 306, G622-G630.	1.6	94
25	The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor. Diabetes, 2017, 66, 2363-2371.	0.3	88
26	Disruption of glucagon receptor signaling causes hyperaminoacidemia exposing a possible liver-alpha-cell axis. American Journal of Physiology - Endocrinology and Metabolism, 2018, 314, E93-E103.	1.8	84
27	Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regulatory Peptides, 2012, 179, 91-100.	1.9	81
28	Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. Diabetologia, 2019, 62, 665-675.	2.9	81
29	Early gradual feeding with bovine colostrum improves gut function and NEC resistance relative to infant formula in preterm pigs. American Journal of Physiology - Renal Physiology, 2015, 309, G310-G323.	1.6	80
30	The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regulatory Peptides, 2011, 168, 32-38.	1.9	77
31	The truncated metabolite GLP-2 (3â€“33) interacts with the GLP-2 receptor as a partial agonist. Regulatory Peptides, 2002, 103, 9-15.	1.9	73
32	Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regulatory Peptides, 2004, 118, 11-18.	1.9	73
33	Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment. Frontiers in Endocrinology, 2019, 10, 75.	1.5	70
34	GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. Diabetologia, 2018, 61, 413-423.	2.9	66
35	Stability of glucagon-like peptide 1 and glucagon in human plasma. Endocrine Connections, 2015, 4, 50-57.	0.8	65
36	Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4541-4552.	1.8	65

#	Article	IF	Citations
37	Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors. Biochemical Pharmacology, 2018, 150, 97-107.	2.0	65
38	Introduction of Enteral Food Increases Plasma GLP-2 and Decreases GLP-2 Receptor mRNA Abundance during Pig Development. Journal of Nutrition, 2003, 133, 1781-1786.	1.3	61
39	Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Journal of Diabetes and Its Complications, 2015, 29, 445-450.	1.2	61
40	The arcuate nucleus is pivotal in mediating the anorectic effects of centrally administered leptin. NeuroReport, 1999, 10, 1183-1187.	0.6	60
41	Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats. Regulatory Peptides, 2002, 105, 173-179.	1.9	59
42	The 2-monoacylglycerol moiety of dietary fat appears to be responsible for the fat-induced release of GLP-1 in humans. American Journal of Clinical Nutrition, 2015, 102, 548-555.	2.2	59
43	Effects of Peripheral Neurotensin on Appetite Regulation and Its Role in Gastric Bypass Surgery. Endocrinology, 2016, 157, 3482-3492.	1.4	58
44	Intestinal growth adaptation and glucagon-like peptide 2 in rats with ileal–jejunal transposition or small bowel resection. Digestive Diseases and Sciences, 2001, 46, 379-388.	1.1	57
45	Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5703-5714.	1.8	57
46	Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery. American Journal of Physiology - Endocrinology and Metabolism, 2016, 310, E505-E514.	1.8	56
47	Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents. Peptides, 2018, 100, 173-181.	1.2	56
48	Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma. EBioMedicine, 2016, 7, 112-120.	2.7	53
49	Long acting analogue of the calcitonin gene-related peptide induces positive metabolic effects and secretion of the glucagon-like peptide-1. European Journal of Pharmacology, 2016, 773, 24-31.	1.7	53
50	GLP-1 amidation efficiency along the length of the intestine in mice, rats and pigs and in GLP-1 secreting cell lines. Peptides, 2014, 55, 52-57.	1.2	52
51	Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 354-363.	3.7	52
52	Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty. European Journal of Endocrinology, 2013, 169, 187-201.	1.9	51
53	Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis. Gut, 2013, 62, 1724-1733.	6.1	50
54	Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY. European Journal of Gastroenterology and Hepatology, 2005, 17, 207-212.	0.8	48

#	Article	IF	Citations
55	Effect of Liraglutide Treatment on Jejunostomy Output in Patients With Short Bowel Syndrome: An Openâ€Łabel Pilot Study. Journal of Parenteral and Enteral Nutrition, 2018, 42, 112-121.	1.3	48
56	Continuous Parenteral and Enteral Nutrition Induces Metabolic Dysfunction in Neonatal Pigs. Journal of Parenteral and Enteral Nutrition, 2012, 36, 538-550.	1.3	47
57	In vivo and in vitro degradation of peptide YY_{3â€“36} to inactive peptide YY_{3â€“34} in humans. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 310, R866-R874.	0.9	46
58	Cephalic phase secretion of insulin and other enteropancreatic hormones in humans. American Journal of Physiology - Renal Physiology, 2016, 310, G43-G51.	1.6	45
59	GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men. Bone, 2019, 125, 178-185.	1.4	45
60	Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects. Bone, 2017, 97, 261-266.	1.4	41
61	Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2953-2960.	1.8	41
62	Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats. American Journal of Physiology - Renal Physiology, 2007, 293, G288-G295.	1.6	40
63	Glutamate prevents intestinal atrophyvialuminal nutrient sensing in a mouse model of total parenteral nutrition. FASEB Journal, 2014, 28, 2073-2087.	0.2	40
64	The glucagon-like peptide 2 receptor is expressed in enteric neurons and not in the epithelium of the intestine. Peptides, 2015, 67, 20-28.	1.2	40
65	Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome. Scandinavian Journal of Gastroenterology, 2008, 43, 1304-1310.	0.6	39
66	Why is it so difficult to measure glucagon-like peptide-1 in a mouse?. Diabetologia, 2017, 60, 2066-2075.	2.9	39
67	No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes. Diabetes Care, 2020, 43, 588-596.	4.3	38
68	Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate. Scandinavian Journal of Gastroenterology, 2007, 42, 814-820.	0.6	37
69	Intestinal Adaptation Is Stimulated by Partial Enteral Nutrition Supplemented With the Prebiotic Shortâ€Chain Fructooligosaccharide in a Neonatal Intestinal Failure Piglet Model. Journal of Parenteral and Enteral Nutrition, 2012, 36, 524-537.	1.3	37
70	Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine. Cancer Chemotherapy and Pharmacology, 2012, 70, 39-48.	1.1	37
71	GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e725-e738.	1.8	37
72	Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial. Diabetologia, 2022, 65, 506-517.	2.9	37

#	Article	IF	Citations
73	The Intestinotrophic Peptide, GLP-2, Counteracts Intestinal Atrophy in Mice Induced by the Epidermal Growth Factor Receptor Inhibitor, Gefitinib. Clinical Cancer Research, 2007, 13, 5170-5175.	3.2	35
74	Glucose stimulates neurotensin secretion from the rat small intestine by mechanisms involving SGLT1 and GLUT2, leading to cell depolarization and calcium influx. American Journal of Physiology - Endocrinology and Metabolism, 2015, 308, E1123-E1130.	1.8	34
75	Dynamics of glucagon secretion in mice and rats revealed using a validated sandwich ELISA for small sample volumes. American Journal of Physiology - Endocrinology and Metabolism, 2016, 311, E302-E309.	1.8	34
76	Potential targets for glucagon-like peptide 2 (GLP-2) in the rat: distribution and binding of i.v. injected 125I-GLP-2. Peptides, 2000, 21, 1511-1517.	1.2	33
77	Plasma GLP-2 Levels and Intestinal Markers in the Juvenile Pig During Intestinal Adaptation: Effects of Different Diet Regimens. Digestive Diseases and Sciences, 2004, 49, 1688-1695.	1.1	33
78	Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion. Journal of Diabetes Research, 2016, 2016, 1-5.	1.0	33
79	Patients With Long-QT Syndrome Caused by Impaired hERG -Encoded K _v 11.1 Potassium Channel Have Exaggerated Endocrine Pancreatic and Incretin Function Associated With Reactive Hypoglycemia. Circulation, 2017, 135, 1705-1719.	1.6	33
80	Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway. Diabetes, 2019, 68, 1329-1340.	0.3	33
81	Functional Ontogeny of the Proglucagon-Derived Peptide Axis in the Premature Human Neonate. Pediatrics, 2008, 121, e180-e186.	1.0	32
82	Rapid gut growth but persistent delay in digestive function in the postnatal period of preterm pigs. American Journal of Physiology - Renal Physiology, 2016, 310, G550-G560.	1.6	32
83	Secretion of Trophic Gut Peptides Is Not Different in Bolus- and Continuously Fed Piglets. Journal of Nutrition, 2001, 131, 729-732.	1.3	31
84	Glucagonâ€like peptideâ€1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men. Physiological Reports, 2017, 5, e13073.	0.7	31
85	Searching for the physiological role of glucoseâ€dependent insulinotropic polypeptide. Journal of Diabetes Investigation, 2016, 7, 8-12.	1.1	30
86	Interdependency of EGF and GLP-2 Signaling in Attenuating Mucosal Atrophy in a Mouse Model of Parenteral Nutrition. Cellular and Molecular Gastroenterology and Hepatology, 2017, 3, 447-468.	2.3	29
87	Extracellular Fluid Volume Expansion Uncovers a Natriuretic Action of GLP-1: A Functional GLP-1â€"Renal Axis in Man. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2509-2519.	1.8	29
88	Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure. Regulatory Peptides, 2013, 181, 4-8.	1.9	28
89	Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production. Cell Reports, 2017, 21, 1452-1460.	2.9	28
90	Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: <scp>A</scp> randomized, placeboâ€controlled, doubleâ€blind, parallelâ€group study. Diabetes, Obesity and Metabolism, 2017, 19, 773-782.	2.2	28

#	Article	IF	Citations
91	Postprandial Dyslipidemia, Hyperinsulinemia, and Impaired Gut Peptides/Bile Acids in Adolescents with Obesity. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1228-1241.	1.8	28
92	Gut hormone release after gastric bypass depends on the length of the biliopancreatic limb. International Journal of Obesity, 2019, 43, 1009-1018.	1.6	27
93	Biliopancreatic diversion with duodenal switch (BPD-DS) and single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) result in distinct post-prandial hormone profiles. International Journal of Obesity, 2019, 43, 2518-2527.	1.6	27
94	Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and longâ€term impairment of the GIP system. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 122-132.	1.2	27
95	Responses of gut and pancreatic hormones, bile acids, and fibroblast growth factor-21 differ to glucose, protein, and fat ingestion after gastric bypass surgery. American Journal of Physiology - Renal Physiology, 2020, 318, G661-G672.	1.6	27
96	Porcine glucagon-like peptide-2: Structure, signaling, metabolism and effects. Regulatory Peptides, 2008, 146, 310-320.	1.9	26
97	The Intestinotrophic Peptide, GLP-2, Counteracts the Gastrointestinal Atrophy in Mice Induced by the Epidermal Growth Factor Receptor Inhibitor, Erlotinib, and Cisplatin. Digestive Diseases and Sciences, 2010, 55, 2785-2796.	1.1	26
98	Stimulation of intestinal growth and function with DPP4 inhibition in a mouse short bowel syndrome model. American Journal of Physiology - Renal Physiology, 2014, 307, G410-G419.	1.6	25
99	GIP and the gut-bone axis â€“ Physiological, pathophysiological and potential therapeutic implications. Peptides, 2020, 125, 170197.	1.2	25
100	The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. Bone, 2020, 140, 115553.	1.4	25
101	Secretin release after Roux-en-Y gastric bypass reveals a population of glucose-sensitive S cells in distal small intestine. International Journal of Obesity, 2020, 44, 1859-1871.	1.6	25
102	Comparative analysis of oral and intraperitoneal glucose tolerance tests in mice. Molecular Metabolism, 2022, 57, 101440.	3.0	25
103	GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in Rats. ACS Pharmacology and Translational Science, 2021, 4, 296-313.	2.5	24
104	The anorexic hormone Peptide YY₃₋₃₆is rapidly metabolized to inactive Peptide YY₃₋₃₄inÂvivo. Physiological Reports, 2015, 3, e12455.	0.7	23
105	Endogenous glucagon-like peptide- 1 and 2 are essential for regeneration after acute intestinal injury in mice. PLoS ONE, 2018, 13, e0198046.	1.1	23
106	Consumption of nutrients and insulin resistance suppress markers of bone turnover in subjects with abdominal obesity. Bone, 2020, 133, 115230.	1.4	23
107	The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 309, R544-R551.	0.9	22
108	Glucagon-like Peptide 1 Receptor Signaling in Acinar Cells Causes Growth-Dependent Release of Pancreatic Enzymes. Cell Reports, 2016, 17, 2845-2856.	2.9	22

#	Article	IF	Citations
109	Fasting Plasma GLP-1 Is Associated With Overweight/Obesity and Cardiometabolic Risk Factors in Children and Adolescents. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1718-1727.	1.8	22
110	Effect of Fecal Microbiota Transplantation Combined With Mediterranean Diet on Insulin Sensitivity in Subjects With Metabolic Syndrome. Frontiers in Microbiology, 2021, 12, 662159.	1.5	22
111	Safety and Dosing Study of Glucagon-Like Peptide 2 in Children With Intestinal Failure. Journal of Parenteral and Enteral Nutrition, 2017, 41, 844-852.	1.3	21
112	Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats. Frontiers in Endocrinology, 2019, 10, 492.	1.5	21
113	Effects of whey protein and dietary fiber intake on insulin sensitivity, body composition, energy expenditure, blood pressure, and appetite in subjects with abdominal obesity. European Journal of Clinical Nutrition, 2021, 75, 611-619.	1.3	21
114	Effects of endogenous GIP in patients with type 2 diabetes. European Journal of Endocrinology, 2021, 185, 33-45.	1.9	21
115	LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men. Cell Reports Medicine, 2022, 3, 100582.	3.3	21
116	Provision of Amniotic Fluid During Parenteral Nutrition Increases Weight Gain With Limited Effects on Gut Structure, Function, Immunity, and Microbiology in Newborn Preterm Pigs. Journal of Parenteral and Enteral Nutrition, 2016, 40, 552-566.	1.3	20
117	GIPâ€™s effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3â€“30)NH2. Bone, 2020, 130, 115079.	1.4	20
118	Alpha-Lactalbumin Enriched Whey Protein Concentrate to Improve Gut, Immunity and Brain Development in Preterm Pigs. Nutrients, 2020, 12, 245.	1.7	20
119	Effects of a diet rich in arabinoxylan and resistant starch compared with a diet rich in refined carbohydrates on postprandial metabolism and features of the metabolic syndrome. European Journal of Nutrition, 2018, 57, 795-807.	1.8	19
120	A Pilot Study Showing Acute Inhibitory Effect of GLPâ€1 on the Bone Resorption Marker CTX in Humans. JBMR Plus, 2019, 3, e10209.	1.3	19
121	Gastric emptying of solutions containing the natural sweetener erythritol and effects on gut hormone secretion in humans: A pilot doseâ€ranging study. Diabetes, Obesity and Metabolism, 2021, 23, 1311-1321.	2.2	19
122	Metabolism of glucagon-like peptide-2 in pigs: Role of dipeptidyl peptidase IV. Regulatory Peptides, 2007, 138, 126-132.	1.9	18
123	Sacubitril/Valsartan Augments Postprandial Plasma Concentrations of Active GLP-1 When Combined With Sitagliptin in Men. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3868-3876.	1.8	18
124	Oral D/L-3-Hydroxybutyrate Stimulates Cholecystokinin and Insulin Secretion and Slows Gastric Emptying in Healthy Males. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3597-e3605.	1.8	18
125	Jejunal feeding is followed by a greater rise in plasma cholecystokinin, peptide YY, glucagon-like peptide 1, and glucagon-like peptide 2 concentrations compared with gastric feeding in vivo in humans: a randomized trial. American Journal of Clinical Nutrition, 2016, 103, 435-443.	2.2	17
126	Hyperosmolar Duodenal Saline Infusion Lowers Circulating Ghrelin and Stimulates Intestinal Hormone Release in Young Men. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4409-4418.	1.8	17

#	Article	IF	Citations
127	Effects of a High-Protein/Moderate-Carbohydrate Diet on Appetite, Gut Peptides, and Endocannabinoidsâ€"A Preview Study. Nutrients, 2019, 11, 2269.	1.7	17
128	Effect of the Natural Sweetener Xylitol on Gut Hormone Secretion and Gastric Emptying in Humans: A Pilot Dose-Ranging Study. Nutrients, 2021, 13, 174.	1.7	17
129	The Antiresorptive Effect of GIP, But Not GLP-2, Is Preserved in Patients With Hypoparathyroidismâ€"A Randomized Crossover Study. Journal of Bone and Mineral Research, 2020, 36, 1448-1458.	3.1	17
130	Effects of an intensive lifestyle intervention on the underlying mechanisms of improved glycaemic control in individuals with type 2 diabetes: a secondary analysis of a randomised clinical trial. Diabetologia, 2020, 63, 2410-2422.	2.9	16
131	Duodenal Anaerobutyricum soehngenii infusion stimulates GLP-1 production, ameliorates glycaemic control and beneficially shapes the duodenal transcriptome in metabolic syndrome subjects: a randomised double-blind placebo-controlled cross-over study. Gut, 2021, , gutjnl-2020-323297.	6.1	16
132	Pancreatic polypeptide responses to isoglycemic oral and intravenous glucose in humans with and without intact vagal innervation. Peptides, 2015, 71, 229-231.	1.2	15
133	Augmented GLP-1 Secretion as Seen After Gastric Bypass May Be Obtained by Delaying Carbohydrate Digestion. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3233-3244.	1.8	15
134	The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. European Journal of Endocrinology, 2021, 184, 383-394.	1.9	15
135	Doseâ€dependent efficacy of the glucoseâ€dependent insulinotropic polypeptide (<scp>GIP)</scp> receptor antagonist <scp>GIP</scp>(3â€30)<scp>NH₂</scp> on <scp>GIP</scp> actions in humans. Diabetes, Obesity and Metabolism, 2021, 23, 68-74.	2.2	14
136	Gastrointestinal Hormones and Î²-Cell Function After Gastric Bypass and Sleeve Gastrectomy: A Randomized Controlled Trial (Oseberg). Journal of Clinical Endocrinology and Metabolism, 2022, 107, e756-e766.	1.8	14
137	A Pilot Study Examining the Relationship among Crohn Disease Activity, Glucagon-Like Peptide-2 Signalling and Intestinal Function in Pediatric Patients. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 587-592.	1.8	13
138	A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite. American Journal of Physiology - Endocrinology and Metabolism, 2017, 313, E284-E291.	1.8	13
139	Fatty Liver Among Adolescent Offspring of Women With Type 1 Diabetes (the EPICOM Study). Diabetes Care, 2019, 42, 1560-1568.	4.3	13
140	Effects of exogenous glucagon-like peptide-2 and distal bowel resection on intestinal and systemic adaptive responses in rats. PLoS ONE, 2017, 12, e0181453.	1.1	13
141	GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment. Pharmacological Research, 2022, 176, 106058.	3.1	13
142	Acute effects of glucagon-like peptide-1, GLP-1_{9-36 amide}, and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers. Physiological Reports, 2017, 5, e13102.	0.7	12
143	Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e502-e510.	1.8	12
144	Enteroendocrine K Cells Exert Complementary Effects to Control Bone Quality and Mass in Mice. Journal of Bone and Mineral Research, 2020, 35, 1363-1374.	3.1	12

#	Article	IF	Citations
145	The Renal Extraction and the Natriuretic Action of GLP-1 in Humans Depend on Interaction With the GLP-1 Receptor. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e11-e19.	1.8	12
146	The diurnal variation of bone formation is attenuated in adult patients with type 2 diabetes. European Journal of Endocrinology, 2019, 181, 221-231.	1.9	12
147	Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young. European Journal of Endocrinology, 2015, 173, 205-215.	1.9	11
148	Differential action of TGR5 agonists on GLP-2 secretion and promotion of intestinal adaptation in a piglet short bowel model. American Journal of Physiology - Renal Physiology, 2019, 316, G641-G652.	1.6	11
149	The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial. Diabetologia, 2020, 63, 1285-1298.	2.9	11
150	Pharmacological activation of TGR5 promotes intestinal growth via a GLP-2-dependent pathway in mice. American Journal of Physiology - Renal Physiology, 2020, 318, G980-G987.	1.6	11
151	Quantitative perfusion assessment of intestinal anastomoses in pigs treated with glucagon-like peptide 2. Langenbeck's Archives of Surgery, 2018, 403, 881-889.	0.8	10
152	A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals. Obesity Surgery, 2020, 30, 1605-1610.	1.1	10
153	Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial. Diabetes Care, 2020, 43, 2889-2893.	4.3	10
154	A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia. Frontiers in Endocrinology, 2020, 11, 608248.	1.5	10
155	GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 150049.	0.2	10
156	64-OR: Postprandial Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide in Type 2 Diabetes. Diabetes, 2019, 68, .	0.3	10
157	Meal induced gut hormone secretion is altered in aerobically trained compared to sedentary young healthy males. European Journal of Applied Physiology, 2013, 113, 2737-2747.	1.2	9
158	Infrared thermographic assessment of changes in skin temperature during hypoglycaemia in patients with type 1 diabetes. Diabetologia, 2015, 58, 1898-1906.	2.9	9
159	Glucose Tolerance Tests and Osteocalcin Responses in Healthy People. Frontiers in Endocrinology, 2018, 9, 356.	1.5	9
160	Glucagon-Like Peptide-1 Is a Marker of Systemic Inflammation in Patients Treated with High-Dose Chemotherapy and Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1085-1091.	2.0	9
161	Neuromedin U Does Not Act as a Decretin in Rats. Cell Metabolism, 2019, 29, 719-726.e5.	7.2	9
162	Glucose homeostasis in statin usersâ€"The LIFESTAT study. Diabetes/Metabolism Research and Reviews, 2019, 35, e3110.	1.7	9

#	Article	IF	Citations
163	Parenteral nutrition impairs plasma bile acid and gut hormone responses to mixed meal testing in lean healthy men. Clinical Nutrition, 2021, 40, 1013-1021.	2.3	9
164	Dietary Fiber Is Essential to Maintain Intestinal Size, L-Cell Secretion, and Intestinal Integrity in Mice. Frontiers in Endocrinology, 2021, 12, 640602.	1.5	9
165	Selective release of gastrointestinal hormones induced by an orally active GPR39 agonist. Molecular Metabolism, 2021, 49, 101207.	3.0	9
166	A safety and pharmacokinetic dosing study of glucagon-like peptide 2 in infants with intestinal failure. Journal of Pediatric Surgery, 2017, 52, 749-754.	0.8	8
167	Acute administration of interleukin-6 does not increase secretion of glucagon-like peptide-1 in mice. Physiological Reports, 2018, 6, e13788.	0.7	8
168	Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study. BMJ Open Gastroenterology, 2021, 8, e000604.	1.1	8
169	Effects of prebiotics on postprandial GLPâ€1, GLPâ€2 and glucose regulation in patients with type 2 diabetes: A randomised, doubleâ€blind, placeboâ€controlled crossover trial. Diabetic Medicine, 2021, 38, e14657.	1.2	8
170	Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study. Bone, 2021, 152, 116065.	1.4	8
171	Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study. Clinical and Translational Gastroenterology, 2020, 11, e00257.	1.3	8
172	The Role of D-allulose and Erythritol on the Activity of the Gut Sweet Taste Receptor and Gastrointestinal Satiation Hormone Release in Humans: A Randomized, Controlled Trial. Journal of Nutrition, 2022, 152, 1228-1238.	1.3	8
173	Intestinal sensing and handling of dietary lipids in gastric bypassâ€“operated patients and matched controls. American Journal of Clinical Nutrition, 2020, 111, 28-41.	2.2	7
174	In vivo positron emission tomography imaging of decreased parasympathetic innervation in the gut of vagotomized patients. Neurogastroenterology and Motility, 2020, 32, e13759.	1.6	7
175	Postprandial renal haemodynamic effects of the dipeptidyl peptidaseâ€4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (<scp>RENALIS</scp>): A predefined substudy of a randomized, doubleâ€blind trial. Diabetes, Obesity and Metabolism, 2022, 24, 115-124.	2.2	7
176	Gluco-metabolic effects of oral and intravenous alcohol administration in men. Endocrine Connections, 2019, 8, 1372-1382.	0.8	7
177	Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 150105.	0.2	7
178	Congenital Glucagon-like Peptide-1 Deficiency in the Pathogenesis of Protracted Diarrhea in Mitchellâ€“Riley Syndrome. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1084-e1090.	1.8	7
179	Hyperglucagonemia in Pediatric Adiposity Associates With Cardiometabolic Risk Factors but Not Hyperglycemia. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1569-1576.	1.8	7
180	Glucoseâ€dependent insulinotropic polypeptide receptor antagonist treatment causes a reduction in weight gain in ovariectomised high fat dietâ€fed mice. British Journal of Pharmacology, 2022, 179, 4486-4499.	2.7	7

#	Article	IF	Citations
181	Pancreatic Polypeptide in Parkinsonâ€™s Disease: A Potential Marker of Parasympathetic Denervation. Journal of Parkinson's Disease, 2017, 7, 645-652.	1.5	6
182	Increased oral sodium chloride intake in humans amplifies selectively postprandial GLPâ€1 but not GIP, CCK, and gastrin in plasma. Physiological Reports, 2020, 8, e14519.	0.7	6
183	Gastric Residual to Predict Necrotizing Enterocolitis in Preterm Piglets As Models for Infants. Journal of Parenteral and Enteral Nutrition, 2021, 45, 87-93.	1.3	6
184	Colonic Lactulose Fermentation Has No Impact on Glucagon-like Peptide-1 and Peptide-YY Secretion in Healthy Young Men. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 77-87.	1.8	6
185	Secretion of parathyroid hormone may be coupled to insulin secretion in humans. Endocrine Connections, 2020, 9, 747-754.	0.8	6
186	Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Diabetes Care, 2022, 45, 1476-1481.	4.3	6
187	Important species differences regarding lymph contribution to gut hormone responses. Peptides, 2015, 71, 28-31.	1.2	5
188	Anorexia and fat aversion induced by vertical sleeve gastrectomy is attenuated in neurotensin receptor 1 deficient mice. Endocrinology, 2021, 162, .	1.4	5
189	Effects of shortâ€acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 221-227.	2.2	5
190	Novel agonistâ€and antagonistâ€based radioligands for the GLPâ€2 receptor â€useful tools for studies of basic GLPâ€2R pharmacology. British Journal of Pharmacology, 2021, , .	2.7	5
191	Acute concomitant glucoseâ€dependent insulinotropic polypeptide receptor antagonism during glucagonâ€like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity. Diabetes, Obesity and Metabolism, 2022, 24, 1882-1887.	2.2	5
192	Weight-loss induced by carbohydrate restriction does not negatively affect health-related quality of life and cognition in people with type 2 diabetes: A randomised controlled trial. Clinical Nutrition, 2022, , .	2.3	5
193	The insulinotropic effect of exogenous glucagonâ€like peptideâ€1 is not affected by acute vagotomy in anaesthetized pigs. Experimental Physiology, 2016, 101, 895-912.	0.9	4
194	No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course. BMC Endocrine Disorders, 2018, 18, 60.	0.9	4
195	No effects of a 6â€week intervention with a glucagonâ€like peptideâ€1 receptor agonist on pancreatic volume and oedema in obese men without diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1837-1846.	2.2	4
196	Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans. Endocrine Connections, 2021, 10, 205-213.	0.8	4
197	Effect of 6 weeks of very lowâ€volume highâ€intensity interval training on oral glucoseâ€stimulated incretin hormone response. European Journal of Sport Science, 2022, 22, 381-389.	1.4	4
198	Î²-Lactoglobulin Is Insulinotropic Compared with Casein and Whey Protein Ingestion during Catabolic Conditions in Men in a Double-Blinded Randomized Crossover Trial. Journal of Nutrition, 2021, 151, 1462-1472.	1.3	4

#	Article	IF	Citations
199	The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial. Diabetologia, 2021, 64, 2425-2431.	2.9	4
200	Effects of a Lifestyle Intervention on Bone Turnover in Persons with Type 2 Diabetes: A Post Hoc Analysis of the U-TURN Trial. Medicine and Science in Sports and Exercise, 2022, 54, 38-46.	0.2	4
201	Worsening Postural Tachycardia Syndrome Is Associated With Increased Glucose-Dependent Insulinotropic Polypeptide Secretion. Hypertension, 2022, 79, HYPERTENSIONAHA12117852.	1.3	4
202	Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy. Frontiers in Nutrition, 2022, 9, 889710.	1.6	4
203	Hypoglycaemia and rebound hyperglycaemia increase left ventricular systolic function in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 2027-2037.	2.2	4
204	Is glucagonâ€like peptideâ€1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?. Diabetes, Obesity and Metabolism, 2018, 20, 1937-1943.	2.2	3
205	Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e564-e574.	1.8	3
206	89-LB: The Effect of GIP on Plasma Glucose in a Setting of Prandial Insulin Overdose and Physical Activity after Meal Intake in Patients with Type 1 Diabetes. Diabetes, 2020, 69, .	0.3	3
207	Glucagon-Like Peptide-1 Is Associated With Systemic Inflammation in Pediatric Patients Treated With Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2021, 12, 793588.	2.2	3
208	Glucagon-Like Peptide-2 in Umbilical Cord Blood from Mature Infants. Neonatology, 2007, 91, 49-53.	0.9	2
209	Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on postâ€meal glucose excursions and glucagon in type 1 diabetes patients. Endocrinology, Diabetes and Metabolism, 2020, 3, e00130.	1.0	2
210	Pharmacokinetics of exogenous GIP(1-42) in C57Bl/6 mice; Extremely rapid degradation but marked variation between available assays. Peptides, 2021, 136, 170457.	1.2	2
211	Preserved postprandial suppression of bone turnover markers, despite increased fasting levels, in postmenopausal women. Bone, 2021, 143, 115612.	1.4	2
212	Intestinal Growth in Glucagon Receptor Knockout Mice Is Not Associated With the Formation of AOM/DSS-Induced Tumors. Frontiers in Endocrinology, 2021, 12, 695145.	1.5	2
213	Neurotensin secretion after Rouxâ€enâ€Y gastric bypass, sleeve gastrectomy, and truncal vagotomy with pyloroplasty. Neurogastroenterology and Motility, 2021, , e14210.	1.6	2
214	Opposing roles of the entero-pancreatic hormone urocortin-3 in glucose metabolism in rats. Diabetologia, 2022, 65, 1018-1031.	2.9	2
215	Restoration of enteroendocrine and pancreatic function after internal hernia and short bowel syndrome in a young woman with gastric bypass - a 2-year follow-up. Physiological Reports, 2018, 6, e13686.	0.7	1
216	Normal insulin sensitivity, glucose tolerance, gut incretin and pancreatic hormone responses in adults with atopic dermatitis. Diabetes, Obesity and Metabolism, 2020, 22, 2161-2169.	2.2	1

#	Article	IF	Citations
217	Effects of a whey protein preâ€meal on bone turnover in participants with and without type 2 diabetesâ€"A post hoc analysis of a randomised, controlled, crossover trial. Diabetic Medicine, 2021, 38, e14471.	1.2	1
218	The Effect of Melatonin on Incretin Hormones: Results From Experimental and Randomized Clinical Studies. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e5109-e5123.	1.8	1
219	Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in Beta Cell Function in Patients with Type 2 Diabetes. Diabetes, 0, , .	0.3	1